Thalassemia and venous thromboembolism
63:e01403-19
These results indicate that GOx/CuSAE-induced metabolic disruptions contribute to disulfide accumulation and oxidative stress in cells, which collectively promote disulfidptosis with complementary effects of ferroptosis
Disclosures: Emmanuel Dixon: Nothing to Disclose, thierry claudel: Nothing to Disclose, Jakob-Wendelin Genger: Nothing to Disclose, Ci Zhu: Nothing to Disclose, Sarah Stadlmayr: Nothing to Disclose, Erika Paolini: Nothing to Disclose, Alexander Nardo: Nothing to Disclose, Veronika Mlitz: Nothing to Disclose, Claudia Fuchs: Nothing to Disclose, Andreas Bergthaler: Nothing to Disclose, Paola Dongiovanni: Nothing to Disclose, Wilfried Ellmeier: Nothing to Disclose, Michael Trauner: Albireo: Grant/Research Support, Alnylam: Grant/Research Support, Cymabay: Grant/Research Support, Falk: Grant/Research Support, Gilead: Grant/Research Support, Intercept: Grant/Research Support, MSD: Grant/Research Support, Takeda: Grant/Research Support, Ultragenyx: Grant/Research Support, Abbvie: Travel Grants, Falk: Travel Grants, Gilead: Travel Grants, Intercept: Travel Grants, Janssen: Travel Grants, Abbvie: Advisor, Albireo: Advisor, BiomX: Advisor, Boehringer Ingelheim: Advisor, Falk Pharma GmbH: Advisor, Genfit: Advisor, Gilead: Advisor, Hightide: Advisor, Intercept: Advisor, Ipsen: Advisor, Janssen: Advisor, MSD: Advisor, Novartis: Advisor, Phenex: Advisor, Pliant: Advisor, Regulus: Advisor, Siemens: Advisor, Shire: Advisor, BMS: Speaking and Teaching, Falk: Speaking and Teaching, Gilead: Speaking and Teaching, Intercept: Speaking and Teaching, Ipsen: Speaking and Teaching, Madrigal: Speaking and Teaching, MSD: Speaking and Teaching, Medical Universities of Graz and Vienna: Co.Inventor of patents for medical use of norUDCA filed by 2630 S-ADENOSYLMETHIONINE PROTECTS AGAINST FOLFOX-INDUCED LIVER INJURY BY INHIBITING PLASMINOGEN ACTIVATOR INHIBITOR-1 IN MICE Alexandra Gangi 1 Youngyi Lim 1 Tony Li 1 Andrea Floris 1 Swati Chandla 1 Maria Lauda Tomasi 1 Shelly Lu 1 , 1 Cedars Sinai Medical Center Background: Folinic acid, 5-Fluorouracil and Oxaliplatin (FOLFOX), a commonly used chemotherapeutic regimen in patients with colorectal liver metastasis (CRLM), can cause liver injury such as sinusoidal obstruction syndrome (SOS) that limits further treatment
Text us and well help you compare options at your consultation
Curr Pharm Des 11(21):2779-2795, 2005
